Journal
CELL RESEARCH
Volume 22, Issue 1, Pages 237-247Publisher
SPRINGERNATURE
DOI: 10.1038/cr.2011.127
Keywords
Wnt pathway; Axin/beta-catenin complex; small molecule; mesenchymal stem cell
Categories
Funding
- SK Biopharmaceuticals Co., Ltd
- Kookmin University in Korea
- National Research Foundation of Korea (NRF)
- Ministry of Education, Science and Technology [2009-0072221]
Ask authors/readers for more resources
The Wnt/beta-catenin pathway plays important roles in the differentiation of multiple cell types, including mesenchymal stem cells. Using a cell-based chemical screening assay with a synthetic chemical library of 270 000 compounds, we identified the compound SKL2001 as a novel agonist of the Wnt/beta-catenin pathway and uncovered its molecular mechanism of action. SKL2001 upregulated beta-catenin responsive transcription by increasing the intracellular beta-catenin protein level and inhibited the phosphorylation of beta-catenin at residues Ser33/37/Thr41 and Ser45, which would mark it for proteasomal degradation, without affecting CK1 and GSK-3 beta enzyme activities. Biochemical analysis revealed that SKL2001 disrupted the Axin/beta-catenin interaction, which is a critical step for CK1- and GSK-3 beta-mediated phosphorylation of beta-catenin at Ser33/37/Thr41 and Ser45. The treatment of mesenchymal stem cells with SKL2001 promoted osteoblastogenesis and suppressed adipocyte differentiation, both of which were accompanied by the activation of Wnt/beta-catenin pathway. Our findings provide a new strategy to regulate mesenchymal stem cell differentiation by modulation of the Wnt/beta-catenin pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available